Nantes-based Biofortis and Teranga, a family-owned holding company, have successfully completed a joint acquisition of Neovix Biosciences, a group operating in the Paris region. This carefully structured deal allows each company to acquire the activities that best fit their respective strategies and areas of expertise. Experts from AURIS Finance, a mergers and acquisitions consultancy, share their insights and analysis.
The Nantes-based Biofortis group, which specialises in clinical research for the pharmaceutical, agri-food and cosmetics industries, has teamed up with the family-owned holding company Teranga to carry out a major restructuring operation. Together, they have acquired the core operations of Neovix Biosciences, a group based in the Hauts-de-Seine department near Paris. Teranga, headquartered in the Loiret region, brings together several companies specialising in human and veterinary health and cosmetics, and also offers microbiology, analysis and consulting services for pharmaceutical and cosmetics laboratories.
A wide range of expertise
Neovix Biosciences is a leading company in the pharmaceutical and cosmetics regulatory and compliance sector. The group recently recorded a turnover of €7.5 million. It employs 70 people and comprises four specialised divisions: Cosmetic Office, a consulting agency dedicated to cosmetics, specialising in marketing and regulatory affairs. Neovix Biosciences also owns AR2i, a research and development laboratory, as well as Qualilab, a consulting and training firm that specialises in quality management and information system compliance. Finally, White-Tillet supports its industrial clients in their development and registration projects. Founded in 1994, White-Tillet joined the Neovix Biosciences group in 2020.
Splitting activities and departments
This joint acquisition, finalised in March 2025, involved the division of Neovix’s activities between Biofortis and Teranga through the establishment of a joint holding company called PEEB. Biofortis will take control of the regulatory, quality, audit, training and formulation activities carried out by AR2i, Cosmetic Office, White-Tillet and Qualibab. These activities represent 80% of Neovix’s business. Meanwhile, Teranga will take over the analytical activities of the AR2i laboratory separately through its subsidiary CEBIPHAR, splitting them between its sites in Fondettes and Toulouse to ensure continuity of service for industrial customers.
Aiming for Europe
This major operation will enable Biofortis to expand its range of services, increase its area of expertise and speed up its growth in pharmaceutical and medical device development. The objective is to achieve €14 million in revenue by 2025, up from €10 million in 2024, with the ambition of becoming a European leader in nutrition and microbiota-related clinical research.
Our experts at your service
As with the transaction carried out by Biofortis and Teranga, joint acquisitions can enable companies to acquire highly attractive assets. However, this depends on the scope of each entity being defined in advance. At the time of the acquisition, the two groups emphasised the complementary nature of their respective areas of expertise: Teranga focuses more on chemical analysis, while Biofortis concentrates on biology and clinical studies. AURIS Finance’s experts specialise by sector. We are here to support you in developing your business. Whether you are looking for financing or a targeted acquisition, our experts can help.
